Liraglutide-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Liraglutide (Brand name: Victoza, Saxenda, others), a GLP-1 receptor agonist used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 7/May/2019, 6.36 am
Liraglutide-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Liraglutide (Brand name: Victoza, Saxenda, others), a GLP-1 receptor agonist used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 7/May/2019, 6.36 am
Spread the love
Spread the love
Let's have a chat!
Sign-up for our newsletter to learn more about upcoming Genomediscovery Forums!